Patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma that received Imbruvica (ibrutinib) in combination with bendamustine and rituximab experienced an 80 percent reduction in the risk of progression or death when compared to patients receiving bendamustine, rituximab and placebo in a phase III trial.
A curious piece of paper hangs in a frame outside the director’s office at University of Iowa Holden Comprehensive Cancer Center on the second floor of the General Hospital.
